Altre lingue Pharvaris N.V.

Azioni

PHVS

NL00150005Y4

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 31/05/2024			Variaz. 5gg	Var. 1 gen.
18,96 ^USD	+0,32%		-6,05%	-32,41%

09/05	PHARVARIS N.V. : Wedbush mantiene la raccomandazione Buy	ZM
08/05	Pharvaris N.V. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

PHARVARIS N.V. : Wedbush toujours positif	09/05
Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024	08/05
PHARVARIS N.V. : Morgan Stanley réitère son opinion positive sur le titre	15/04
Pharvaris Narrows Q4 Net Loss; Hires New CFO	10/04
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04
PHARVARIS N.V. : Opinion positive de JMP Securities	23/01
Pharvaris Says FDA Lifts Clinical Hold on Application for Potential Treatment of Hereditary Angioedema Attacks	22/01
Correction: Sector Update: Health Care Stocks Mixed Pre-Bell Monday	22/01
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	22/01
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks	22/01
Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023	09/12
PHARVARIS N.V. : Morgan Stanley à l'achat	07/12
PHARVARIS N.V. : Wedbush reste à l'achat	06/12
Sector Update: Health Care Stocks Mixed Premarket Wednesday	06/12
Sector Update: Health Care	06/12
Pharvaris' Phase 2 Study of Deucrictibant Meets Primary Endpoint; Prices $300 Million Offering; Shares Jump 42% Pre-Bell	06/12
Top Premarket Gainers	06/12
Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks	06/12
Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer	15/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Pharvaris N.V.

Azioni

PHVS

NL00150005Y4

Altre lingue

Filtri